Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Malignant pleural mesothelioma (MPM) patients whose tumor expresses a protein called PD-L1 are more likely to have a poor clinical outcome, according to a study published in the Journal of ... Read more
Dovitinib seems to have only minimal activity in patients with malignant pleural mesothelioma (MPM) previously treated with chemotherapy. This is according to the results of a Phase 2 clinical trial ... Read more
There is no clear evidence supporting the benefits of second-line active treatments for patients with malignant pleural mesothelioma (MPM) whose first line of treatment failed. This is according to an ... Read more
Quantitative 18F-FDG positron emission tomography/computed tomography (PET/CT) parameters based on pre-treatment tumor volume could be used as surrogate markers to predict the expected course of malignant pleural mesothelioma and help ... Read more
Occupational cancer should be considered in all cases of workplace asbestos exposure according to a case study published in the Romanian Journal of Morphology and Embryology. Moreover, an accurate assessment ... Read more
The U.S. Food and Drug Administration (FDA) recently accepted an Investigational New Drug (IND) application for tazemetostat as a potential treatment of mesothelioma in adults. The decision allows Epizyme, the company developing tazemetostat, ... Read more